- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02134574
Prospective Cohort With Hemopathy in Languedoc-Roussillon (HemoDiag)
December 31, 2021 updated by: University Hospital, Montpellier
Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.
Study Type
Observational
Enrollment (Anticipated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Valerie ROUILLE
- Email: v-rouille@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France
- Recruiting
- Hematology department - UHMontpellier Saint éloi
-
Principal Investigator:
- Guillaume Cartron
-
Contact:
- Valerie ROUILLE
- Email: v-rouille@chu-montpellier.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patient for suspected haematological disease and justifying further exploration
Description
Inclusion criteria:
- Age over 18
- Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
- Having signed an informed consent
- Affiliated with a social security scheme
Exclusion criteria:
- Minor or major protected
- Patients who have received treatment for hematological pathology
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
hematologic malignancy
hematologic malignancy with a sampling of blood
|
hematologic malignancy with a sampling of blood
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival with 2 years
Time Frame: 2 years
|
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival with 5 years
Time Frame: 5 years
|
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
|
5 years
|
Survival with 10 years
Time Frame: 10 years
|
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: GUILLAUME CARTRON, University Hospital, Montpellier
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Anticipated)
June 1, 2033
Study Completion (Anticipated)
June 1, 2033
Study Registration Dates
First Submitted
April 22, 2014
First Submitted That Met QC Criteria
May 6, 2014
First Posted (Estimate)
May 9, 2014
Study Record Updates
Last Update Posted (Actual)
January 4, 2022
Last Update Submitted That Met QC Criteria
December 31, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Beckman Coulter, Inc.The First Affiliated Hospital with Nanjing Medical University; Institute of... and other collaboratorsRecruitingHematologic Diseases | Hematologic Neoplasms | Hematologic MalignancyChina
Clinical Trials on hematologic malignancy
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Janssen Korea, Ltd., KoreaCompletedNeutropenia | Fever | Hematological Malignancies
-
Chang Gung Memorial HospitalActive, not recruitingUrothelial CarcinomaTaiwan
-
Beni-Suef UniversityRecruiting
-
University of PadovaCompleted
-
RenJi HospitalRecruitingEpithelial Ovarian CancerChina
-
Skin Analytics LimitedInnovate UKCompleted
-
Skin Analytics LimitedCompletedBasal Cell Carcinoma | Squamous Cell Carcinoma | Malignant Skin Melanoma T0United States, Italy
-
Skin Analytics LimitedInnovate UKCompleted